The safety of switching between therapeutic proteins

This publication has 71 references indexed in Scilit:

• Consequences of Brand Switches During the Course of Pediatric Growth Hormone Treatment
  Endocrine Practice, 2012
• Biosimilars – Global issues, national solutions
  Biologicals, 2011
• Biosimilars of Biological Drug Therapies
  Drugs, 2011
• Biosimilars—why terminology matters
  Nature Biotechnology, 2011
• Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation
  Haematologica, 2011
• Biosimilar agents in oncology/haematology: from approval to practice
  European Journal of Haematology, 2010
• Biosimilars and Regulatory Authorities
  Nephron Clinical Practice, 2010
• Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council
  Nephrology Dialysis Transplantation, 2008
• Under-Reporting of Adverse Drug Reactions
  Drug Safety, 2006
• Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002
  Archives of internal medicine (1960), 2005